NASDAQ$IMRX

Immuneering Corporation · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Headline financials

Total Revenue

$665K

No prior period
EPS (adj)

-$1.18

No prior period
Capital Expenditures

$38.1K

No prior period
Free Cash Flow

-$5.49M

No prior period
Net Income

-$5.84M

No prior period
Operating Income

-$5.84M

No prior period
Gross Profit

$192K

No prior period
Cash & Equivalents

$37.1M

No prior period
Total Assets

$38.4M

No prior period
Stock-Based Comp

$217K

No prior period

Revenue & EPS history

Immuneering · Revenue · Quarterly

$665K

Q4 2020
Beat estimate in 3 of 8 quarters(38%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports

Historical avg

-4.3%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+3.7%

Avg return

30 days after

23%

5 / 22 earnings

Positive

+8.3%

Q4 2022

Best reaction

-13.0%

Q4 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+6.8%+13.5%+9.4%
Q3 2025-2.4%+8.0%-8.2%
Q1 2025+4.9%+0.7%+64.6%
Q4 2024-1.8%+0.6%-24.4%
Q3 2024+6.0%-1.6%-10.7%
Q2 2024-6.6%-10.7%-2.5%
Q1 2024-1.2%-12.1%-14.5%
Q4 2023-0.8%+3.2%-53.4%
Q3 2023-12.1%-10.8%+24.9%
Q2 2023-2.2%-6.4%-15.7%
Q1 2023-9.3%-11.2%-0.6%
Q4 2022+8.3%+47.9%+64.2%
Q3 2022-12.5%-16.3%-40.1%
Q2 2022-5.7%-1.5%+32.2%
Q1 2022+3.0%+17.2%+49.9%
Q4 2021-7.3%-6.3%+1.0%
Q3 2021-5.4%-10.2%-29.5%
Q3 2020-5.4%-10.2%-29.5%
Q1 2021-13.0%+8.5%+16.2%
Q2 2021-13.0%+8.5%+16.2%
Q2 2020-13.0%+8.5%+16.2%
Q4 2020-13.0%+8.5%+16.2%
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro